10-Q: Biomerica Q2 Loss Widens Amid Sales Decline, Going Concern Doubts

Biomerica reported a significant net sales decline and increased operating losses for Q2 2026, raising substantial doubt about its ability to continue as a going concern despite a one-time tax credit.

Summary

• Net sales for the three months ended November 30, 2025, decreased by 26% to $1,210,000 from $1,636,000 in the prior year.
• Net sales for the six months ended November 30, 2025, decreased by 25% to $2,590,000 from $3,444,000 in the prior year.
• The company reported a net loss of $1,320,000 for the three months ended November 30, 2025, compared to a net loss of $950,000 for the same period in 2024.
• For the six months ended November 30, 2025, the net loss was $1,318,000, an improvement from $2,266,000 in the prior year, primarily due to a one-time $1,100,000 Employee Retention Credit (ERC) refund.
• Operating loss for the three months increased to $1,373,000 from $993,000, and for the six months increased to $2,489,000 from $2,363,000.
• Cash and cash equivalents increased to $2,543,000 as of November 30, 2025, from $2,399,000 as of May 31, 2025.
• The company raised net proceeds of $1,395,000 from an At-The-Market (ATM) offering during the six months ended November 30, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern, citing insufficient cash to meet operating requirements for the next twelve months.
• Slower-than-expected launches of key new products, inFoods IBS and hp+detect, led to significant cost-cutting measures.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including significant revenue declines, widening operating losses, and an explicit 'going concern' warning. While a one-time tax credit provided a temporary cash boost and capital was raised through an ATM offering, these are insufficient to offset the underlying operational weaknesses and liquidity concerns. The slower-than-expected launch of new products further dampens prospects, indicating high risk.

Positives

• Received a one-time $1,100,000 cash refund from the IRS for the Employee Retention Credit (ERC) during the six months ended November 30, 2025.
• Cash and cash equivalents increased by $144,000 to $2,543,000 as of November 30, 2025, compared to May 31, 2025.
• Working capital improved to $3,592,000 as of November 30, 2025, from $3,135,000 as of May 31, 2025.
• Successfully raised $1,395,000 in net proceeds through an At-The-Market (ATM) offering during the six months ended November 30, 2025.
• Received FDA clearance for hp+detect, a diagnostic test for H. pylori bacteria, in December 2023.
• InFoods IBS product is undergoing phased commercialization with generally positive feedback from GI physician groups, and a reimbursement price has been established by CMS for Medicare.

Negatives

• Consolidated net sales decreased by 26% for the three months and 25% for the six months ended November 30, 2025, compared to the prior year.
• Gross profit significantly declined by 88.3% for the three months and 34.1% for the six months ended November 30, 2025.
• Net loss increased to $1,320,000 for the three months ended November 30, 2025, from $950,000 in the prior year.
• Operating loss increased for both the three-month and six-month periods ended November 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, with current cash insufficient for the next twelve months of operations.
• Slower-than-expected launch of key new products, inFoods IBS and hp+detect, necessitated significant cost-cutting measures.
• Selling, general and administrative expenses increased by 5% for the three months and 1% for the six months, partly due to increased credit loss expense related to aged receivables.

Risks

• Ability to raise additional capital and continue as a going concern.
• Accuracy of estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
• Scope of protection for intellectual property rights covering products and technology.
• Ability to compete in the industry against competitors with significantly greater financial, technical, and marketing resources.
• Ability to obtain and maintain government or regulatory certification in countries and regions where products are sold.
• Ability to maintain relations with key distributors.
• Impact of global economic and political developments, including rising inflation, interest rates, capital market disruptions, and economic slowdowns.
• Risks related to third parties asserting intellectual property infringement claims.
• Impact of numerous laws and regulations and compliance with them.
• Risks related to product recalls, claims of liability, and harm to patients or users of products.
• Ability to retain key personnel and to identify, hire, and retain additional qualified professionals.
• Uncertainties related to international trade policies, tariffs, and supply chain dynamics.

Future Outlook

The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, and seek additional financing through debt or equity issuance to address capital needs and sustain operations beyond the next year. They are continuing the phased commercialization of inFoods IBS, expanding their physician network, and evaluating distribution and licensing opportunities. Efforts are underway to secure U.S. government payment (Medicare) and private payer reimbursement for inFoods IBS. The hp+detect test is being actively marketed to large end-customer laboratories. The company is also focusing on alternative manufacturing and shipping strategies through its European and Mexican subsidiaries to mitigate risks from global economic conditions and trade policies.

Management Comments

• "Our current cash and cash equivalents are insufficient to meet our operating cash requirements and strategic growth objectives for the next twelve months."
• "To address our capital needs and sustain operations beyond the next year, we are actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity issuance, and seek other strategic alternatives."
• "Due to the slower-than-expected launch of our key new products, inFoods IBS and hp+detect, we initiated significant cost-cutting measures to extend our cash runway and work towards increasing revenues to cover overhead costs."
• "Management believes this diversified portfolio approach supports near-term cash generation while advancing longer-term growth initiatives."
• "While the establishment of a reimbursement price does not guarantee coverage, utilization, or payment, management believes it represents an important step toward broader market access."

Industry Context

The company operates in the biomedical technology and diagnostic market, focusing on point-of-care and clinical laboratory products, particularly for gastrointestinal diseases like IBS and H. pylori. The industry is characterized by technological advancements enabling rapid diagnostic tests and a shift towards diagnostic-guided therapies. The company's strategy to balance established products with newer DGT products like inFoods IBS and hp+detect aligns with trends towards personalized medicine and early disease detection. However, the slower-than-expected launch of new products highlights the challenges of commercialization and market adoption in a competitive and regulated environment, especially when facing larger competitors with greater resources.

Comparison to Industry Standards

• NA

Legal Proceedings

• No material legal proceedings were pending as of November 30, 2025. However, the outcome of any future legal matters could have a material adverse effect on financial results.

Related Party Transactions

• The company has an investment of approximately $165,000 in a privately held Polish distributor, owning approximately 6% of the entity.

Stakeholder Impact

• Shareholders face significant risk due to the 'going concern' warning, persistent losses, and potential for further dilution from future capital raises.
• Employees may be impacted by ongoing cost-cutting measures and the need to maintain critical operations with a substantially reduced workforce.
• Customers could experience uncertainty regarding product availability and long-term support if the company's financial viability deteriorates.
• Creditors face increased risk given the company's liquidity challenges and the stated insufficiency of cash to meet future obligations.

Next Steps

• Expand the network of GI physician practices for inFoods IBS and onboard additional practices.
• Evaluate and work with distribution, partnership, and licensing opportunities with U.S. companies for inFoods IBS.
• Pursue U.S. government payment or reimbursement for the inFoods IBS product through the Medicare system.
• Pursue reimbursement with private payer insurance companies for inFoods IBS once Medicare reimbursement is achieved.
• Actively market hp+detect to large end-customer laboratories and position the product for commercial adoption.
• Implement strategies to increase sales, reduce expenses, and sell non-core assets.
• Seek additional financing through debt or equity issuance and explore other strategic alternatives.

Key Dates

Recommendation

The company's explicit 'going concern' warning, coupled with significant and persistent declines in net sales, widening operating losses, and negative cash flow from operations, indicates severe financial distress. While a one-time tax credit provided a temporary cash infusion and capital was raised through an ATM offering, these measures are insufficient to address the fundamental operational challenges and long-term liquidity needs. The slower-than-expected launch of new products further compounds the risk. The high uncertainty regarding future viability and the deteriorating financial performance make this a high-risk investment with a strong likelihood of further share price depreciation.

Keywords

Biomerica, BMRA, 10-Q, Quarterly Report, Financial Results, Diagnostic Products, inFoods IBS, H. pylori, hp+detect, Medical Technology, Point-of-Care, Clinical Laboratories, Gastrointestinal Diseases, IBS, FDA Clearance, SEC Filing, Going Concern, Capital Raise, Revenue Decline, Net Loss, Biomedical Technology